ANI Pharmaceuticals (ANIP)  said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of ...

ANI Pharmaceuticals acquiring Alimera Sciences for $5.50 per share with potential for $0.50 per share CVR, offering an ...

We feel now is a pretty good time to analyse Alimera Sciences, Inc.'s (NASDAQ:ALIM) business as it appears the company may be ...

The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a ...

Alimera Sciences files lawsuit against ANI Pharmaceuticals over failed merger, causing stock to plummet 25% in premarket ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on ANI Pharmaceuticals (ANIP – Research Report), ...

Alpharetta-based Alimera (NASDAQ:ALIM) Sciences Inc. (NASDAQ:ALIM) has finalized its merger with ANI Pharmaceuticals (NASDAQ:ANIP), Inc., as announced in a recent SEC filing. The pharmaceutical ...

PRINCETON - ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), a diversified biopharmaceutical company, announced today the finalization of its acquisition process for Alimera (NASDAQ:ALIM) Sciences ...

About Alimera Sciences, Inc. Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and ...

On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 ...

16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences ...